keyword
https://read.qxmd.com/read/38522641/fatostatin-promotes-anti-tumor-immunity-by-reducing-srebp2-mediated-cholesterol-metabolism-in-tumor-infiltrating-t-lymphocytes
#21
JOURNAL ARTICLE
Lei Zhu, Yilin Shi, Zhelong Feng, Dingyi Yuan, Shiduo Guo, Yuxia Wang, Haowen Shen, Yan Li, Fang Yan, Yajing Wang
Aberrant lipid metabolism impacts intratumoral T cell-mediated immune response and tumor growth. Fatostatin functions as an inhibitor of sterol regulatory element binding protein (SREBP) activation. However, the complex effects of fatostatin on cholesterol metabolism in the tumor microenvironment (TME) and its influence on T cell anti-tumor immunity remain unclear. In this study, fatostatin effectively suppressed B16 melanoma, MC38 colon cancer, and Lewis lung cancer (LLC) transplanted tumor growth in immunocompetent mice by reducing SREBPs-mediated lipid metabolism, especially cholesterol levels...
March 22, 2024: European Journal of Pharmacology
https://read.qxmd.com/read/38520926/fertility-and-reproductive-concerns-related-to-the-new-generation-of-cancer-drugs-and-the-clinical-implication-for-young-individuals-undergoing-treatments-for-solid-tumors
#22
REVIEW
Hildur Helgadottir, Alexios Matikas, Josefin Fernebro, Jan-Erik Frödin, Simon Ekman, Kenny A Rodriguez-Wallberg
The treatment landscape of solid tumors has changed markedly in the last years. Molecularly targeted treatments and immunotherapies have been implemented and have, in many cancers, lowered the risk of relapse and prolonged survival. Patients with tumors harboring specific targetable molecular alterations or mutations are often of a younger age, and hence future fertility and family building can be important concerns in this group. However, there are great uncertainties regarding the effect of the new drugs on reproductive functions, including fertility, pregnancy and lactation and how young patients with cancers, both women and men should be advised...
March 11, 2024: European Journal of Cancer
https://read.qxmd.com/read/38520909/ex-vivo-drug-testing-of-patient-derived-lung-organoids-to-predict-treatment-responses-for-personalized-medicine
#23
REVIEW
Josephine A Taverna, Chia-Nung Hung, Madison Williams, Ryan Williams, Meizhen Chen, Samaneh Kamali, Vaishnavi Sambandam, Cheryl Hsiang-Ling Chiu, Pawel A Osmulski, Maria E Gaczynska, Daniel T DeArmond, Christine Gaspard, Maria Mancini, Meena Kusi, Abhishek N Pandya, Lina Song, Lingtao Jin, Paolo Schiavini, Chun-Liang Chen
Lung cancer is the leading cause of global cancer-related mortality resulting in ∼ 1.8 million deaths annually. Systemic, molecular targeted, and immune therapies have provided significant improvements of survival outcomes for patients. However, drug resistance usually arises and there is an urgent need for novel therapy screening and personalized medicine. 3D patient-derived organoid (PDO) models have emerged as a more effective and efficient alternative for ex vivo drug screening than 2D cell culture and patient-derived xenograft (PDX) models...
March 14, 2024: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://read.qxmd.com/read/38520879/platinum-based-targeted-chemotherapies-and-reversal-of-cisplatin-resistance-in-non-small-cell-lung-cancer-nsclc
#24
REVIEW
Hassaan Umar, Habibah A Wahab, Ali Attiq, Muhammad Wahab Amjad, Syed Nasir Abbas Bukhari, Waqas Ahmad
Lung cancer is the one of the most prevalent cancer in the world. It kills more people from cancer than any other cause and is especially common in underdeveloped nations. With 1.2 million instances, it is also the most prevalent cancer in men worldwide, making about 16.7% of the total cancer burden. Surgery is the main form of curative treatment for early-stage lung cancer. However, the majority of patients had incurable advanced non-small cell lung cancer (NSCLC) recurrence after curative purpose surgery, which is indicative of the aggressiveness of the illness and the dismal outlook...
March 19, 2024: Mutation Research
https://read.qxmd.com/read/38520605/pioneering-the-way-the-revolutionary-potential-of-antibody-drug-conjugates-in-nsclc
#25
REVIEW
Xiehui Chen, Changchun Zeng
Despite targeted therapy and immunotherapy being recognized as established frontline treatments for advanced non-small cell lung cancer (NSCLC), the unavoidable development of resistance and disease progression poses ongoing challenges. Antibody-drug conjugates (ADCs) offer a potent treatment option for NSCLC through the specific delivery of cytotoxic agents to tumor cells that display distinct antigens. This review delves into the latest evidence regarding promising ADC agents for NSCLC, focusing on their targets, effectiveness, and safety assessments...
March 23, 2024: Current Treatment Options in Oncology
https://read.qxmd.com/read/38520221/construction-of-a-prognostic-model-with-cafs-for-predicting-the-prognosis-and-immunotherapeutic-response-of-lung-squamous-cell-carcinoma
#26
JOURNAL ARTICLE
Xiang Zhang, Qingqing Xiao, Cong Zhang, Qinghua Zhou, Tao Xu
Lung squamous cell carcinoma (LUSC) is one of the subtypes of lung cancer (LC) that contributes to approximately 25%-30% of its prevalence. Cancer-associated fibroblasts (CAFs) are key cellular components of the TME, and the large number of CAFs in tumour tissues creates a favourable environment for tumour development. However, the function of CAFs in the LUSC is complex and uncertain. First, we processed the scRNA-seq data and classified distinct types of CAFs. We also identified prognostic CAFRGs using univariate Cox analysis and conducted survival analysis...
April 2024: Journal of Cellular and Molecular Medicine
https://read.qxmd.com/read/38519636/machine-learning-framework-develops-neutrophil-extracellular-traps-model-for-clinical-outcome-and-immunotherapy-response-in-lung-adenocarcinoma
#27
JOURNAL ARTICLE
A Xuan Han, B Yaping Long, C Yao Li, D Di Huang, E Qi Xiong, F Jinfeng Li, G Liangliang Wu, Qiaowei Liu, G Bo Yang, H Yi Hu
Neutrophil extracellular traps (NETs) are novel inflammatory cell death in neutrophils. Emerging studies demonstrated NETs contributed to cancer progression and metastases in multiple ways. This study intends to provide a prognostic NETs signature and therapeutic target for lung adenocarcinoma (LUAD) patients. Consensus cluster analysis performed by 38 reported NET-related genes in TCGA-LUAD cohorts. Then, WGCNA network was conducted to investigate characteristics genes in clusters. Seven machine learning algorithms were assessed for training of the model, the optimal model was picked by C-index and 1-, 3-, 5-year ROC value...
March 22, 2024: Apoptosis: An International Journal on Programmed Cell Death
https://read.qxmd.com/read/38519580/deep-learning-on-tertiary-lymphoid-structures-in-hematoxylin-eosin-predicts-cancer-prognosis-and-immunotherapy-response
#28
JOURNAL ARTICLE
Ziqiang Chen, Xiaobing Wang, Zelin Jin, Bosen Li, Dongxian Jiang, Yanqiu Wang, Mengping Jiang, Dandan Zhang, Pei Yuan, Yahui Zhao, Feiyue Feng, Yicheng Lin, Liping Jiang, Chenxi Wang, Weida Meng, Wenjing Ye, Jie Wang, Wenqing Qiu, Houbao Liu, Dan Huang, Yingyong Hou, Xuefei Wang, Yuchen Jiao, Jianming Ying, Zhihua Liu, Yun Liu
Tertiary lymphoid structures (TLSs) have been associated with favorable immunotherapy responses and prognosis in various cancers. Despite their significance, their quantification using multiplex immunohistochemistry (mIHC) staining of T and B lymphocytes remains labor-intensive, limiting its clinical utility. To address this challenge, we curated a dataset from matched mIHC and H&E whole-slide images (WSIs) and developed a deep learning model for automated segmentation of TLSs. The model achieved Dice coefficients of 0...
March 22, 2024: NPJ Precision Oncology
https://read.qxmd.com/read/38519469/bet-inhibitors-drive-natural-killer-activation-in-non-small-cell-lung-cancer-via-brd4-and-smad3
#29
JOURNAL ARTICLE
Francesca Reggiani, Giovanna Talarico, Giulia Gobbi, Elisabetta Sauta, Federica Torricelli, Veronica Manicardi, Eleonora Zanetti, Stefania Orecchioni, Paolo Falvo, Simonetta Piana, Filippo Lococo, Massimiliano Paci, Francesco Bertolini, Alessia Ciarrocchi, Valentina Sancisi
Non-small-cell lung carcinoma (NSCLC) is the most common lung cancer and one of the pioneer tumors in which immunotherapy has radically changed patients' outcomes. However, several issues are emerging and their implementation is required to optimize immunotherapy-based protocols. In this work, we investigate the ability of the Bromodomain and Extra-Terminal protein inhibitors (BETi) to stimulate a proficient anti-tumor immune response toward NSCLC. By using in vitro, ex-vivo, and in vivo models, we demonstrate that these epigenetic drugs specifically enhance Natural Killer (NK) cell cytotoxicity...
March 22, 2024: Nature Communications
https://read.qxmd.com/read/38516684/multi%C3%A2-omics-approach-to-improve-patient%C3%A2-tailored-therapy-using-immune-checkpoint-blockade-and-cytokine%C3%A2-induced-killer-cell-infusion-in-an-elderly-patient-with-lung-cancer-a-case-report-and-literature-review
#30
Yasi Xing, Fangyuan Qin, Lei Han, Jingwen Yang, Hongrui Zhang, Yong Qi, Shichun Tu, Yaping Zhai
The 5-year survival rate of patients with advanced non-small cell lung cancer (NSCLC) remains low, despite recent advances in targeted therapy and immunotherapy. Therefore, there is a need to identify alternative strategies to improve treatment outcomes. Modern diagnostics can significantly facilitate the selection of treatment plans to improve patient outcomes. In the present study, multi-form diagnostic methodologies were adopted, including next-generation sequencing-based actionable gene sequencing, programmed death ligand 1 (PD-L1) immunohistochemistry, a circulating tumor cell (CTC) assay, flow cytometric analysis of lymphocyte subsets and computed tomography, to improve disease management in an 86-year-old female patient with relapsed metastatic NSCLC...
May 2024: Oncology Letters
https://read.qxmd.com/read/38516472/nephrological-detrimental-impacts-resulting-from-novel-immunotherapy-drugs-used-in-the-treatment-of-cancer-a-systematic-review
#31
REVIEW
Amisha Jaiswal, Kainaat Shergill, Kusalik Boppana, Naiela E Almansouri, Saloni Bakkannavar, Youmna Faheem, Tuheen Sankar Nath
The most recent advancements in cancer therapy center on efficiently and conveniently enhancing a patient's natural immune system. Immune checkpoint inhibitors (ICIs) are antibodies that target cytotoxic thymus (T) lymphocyte antigen-4 (CTLA-4) and its receptor. They function by stimulating T-cell activity against malignancies. Immune-related adverse events (irAEs) are a distinct class of inflammatory side effects that are specific to a given organ. Antineoplastic medications can impact any part of the kidney, leading to the development of proteinuria, hypertension, electrolyte abnormalities, glomerulonephritis, and both acute and chronic interstitial nephritis...
February 2024: Curēus
https://read.qxmd.com/read/38515756/deeplion2-deep-multi-instance-contrastive-learning-framework-enhancing-the-prediction-of-cancer-associated-t-cell-receptors-by-attention-strategy-on-motifs
#32
JOURNAL ARTICLE
Xinyang Qian, Guang Yang, Fan Li, Xuanping Zhang, Xiaoyan Zhu, Xin Lai, Xiao Xiao, Tao Wang, Jiayin Wang
INTRODUCTION: T cell receptor (TCR) repertoires provide valuable insights into complex human diseases, including cancers. Recent advancements in immune sequencing technology have significantly improved our understanding of TCR repertoire. Some computational methods have been devised to identify cancer-associated TCRs and enable cancer detection using TCR sequencing data. However, the existing methods are often limited by their inadequate consideration of the correlations among TCRs within a repertoire, hindering the identification of crucial TCRs...
2024: Frontiers in Immunology
https://read.qxmd.com/read/38515751/cd81-and-cd82-expressing-tumor-infiltrating-lymphocytes-in-the-nsclc-tumor-microenvironment-play-a-crucial-role-in-t-cell-activation-and-cytokine-production
#33
JOURNAL ARTICLE
Kwangmin Na, Seul Lee, Dong Kwon Kim, Young Seob Kim, Joon Yeon Hwang, Seong-San Kang, Sujeong Baek, Chai Young Lee, Seung Min Yang, Yu Jin Han, Mi Hyun Kim, Heekyung Han, Youngtaek Kim, Jae Hwan Kim, Seunghyun Jeon, Youngseon Byeon, Jii Bum Lee, Sun Min Lim, Min Hee Hong, Kyoung-Ho Pyo, Byoung Chul Cho
INTRODUCTION: To understand the immune system within the tumor microenvironment (TME) of non-small cell lung cancer (NSCLC), it is crucial to elucidate the characteristics of molecules associated with T cell activation. METHODS: We conducted an in-depth analysis using single-cell RNA sequencing data obtained from tissue samples of 19 NSCLC patients. T cells were classified based on the Tumor Proportion Score (TPS) within the tumor region, and molecular markers associated with activation and exhaustion were analyzed in T cells from high TPS areas...
2024: Frontiers in Immunology
https://read.qxmd.com/read/38515725/knowledge-domains-and-emerging-trends-in-immune-related-adverse-events-from-immune-checkpoint-inhibitors-a-bibliometrics-and-visualized-analysis
#34
JOURNAL ARTICLE
Jun Zhao, Yujie Feng, Guang-Wei Liu
OBJECTIVE: The primary objective of this paper is to investigate the research hotspots and future trends of immune-related adverse events induced by immune checkpoint inhibitors, offering valuable insights for researchers in this field. METHODOLOGY: Using the visual analysis software, this study conducted quantitative statistics and visualization research on the relevant literature concerning immune-related adverse events caused by immune checkpoint inhibitors in the Web of Science Core Collection Database...
March 30, 2024: Heliyon
https://read.qxmd.com/read/38515651/anlotinib-plus-tislelizumab-for-recurrent-metastatic-pancreas-ductal-adenocarcinoma-with-germline-brca2-mutation-a-case-report
#35
Sujuan Peng, Hongxiang Huang, Xie Zhu, Jinhong Chen, Xinjing Ding, Fen Wang, Li Chen, Zhihui Lu
While combined immunotherapy and anti-angiogenic therapy have demonstrated efficacy in renal cell carcinoma, non-small cell lung cancer and hepatocellular carcinoma, the efficacy of first-line treatment for pancreatic ductal adenocarcinoma (PDAC) with germline BRCA2 mutation remains unproven. We described a BRCA2-mutated patient with PDAC who presented with posterior cardiac metastasis 8 months after surgery. After receiving four cycles of anlotinib combined with tislelizumab, abdominal CT scans indicated a complete response...
May 2024: Experimental and Therapeutic Medicine
https://read.qxmd.com/read/38515570/efficacy-and-safety-of-pembrolizumab-as-first-line-treatment-for-advanced-non-small-cell-lung-cancer-complicated-with-chronic-obstructive-pulmonary-disease-protocol-for-a-prospective-single-arm-single-center-phase-ii-clinical-trial
#36
JOURNAL ARTICLE
Weigang Dong, Yan Yin, Bin Liu, Yan Jiang, Lei Wang, Dongsheng Shi, Jianwen Qin
BACKGROUND: The first-line standard treatment option for patients with NSCLC complicated with Chronic obstructive pulmonary disease (COPD) is still unclear and relies on the treatment option of NSCLC alone. To date, a limited number of retrospective studies have explored the efficacy and safety of immunotherapy in patients with NSCLC complicated with COPD. We therefore designed this study to further explore the efficacy and safety of first-line immunotherapy in patients with NSCLC complicated with COPD...
2024: Frontiers in Oncology
https://read.qxmd.com/read/38515565/ferroptosis-in-lung-cancer-dual-role-multi-level-regulation-and-new-therapeutic-strategies
#37
REVIEW
Yunbin Li, Xiaosong Li, Jian Li
Lung cancer is a highly prevalent malignant tumor worldwide, with high incidence and death rates. Recently, there has been increasing recognition of the role of ferroptosis, a unique cell death mechanism, in lung cancer. This review aims to summarize the current research progress on the relationship between ferroptosis and lung cancer. It also provides a comprehensive analysis of the regulatory processes of ferroptosis in various stages, including epigenetics, transcription, post-transcription, translation, and post-translation...
2024: Frontiers in Oncology
https://read.qxmd.com/read/38515109/gpx8-cancer-associated-fibroblast-as-a-cancer-promoting-factor-in-lung-adenocarcinoma-is-related-to-the-immunosuppressive-microenvironment
#38
JOURNAL ARTICLE
Ying Bai, Tao Han, Yunjia Dong, Chao Liang, Lu Gao, Yafeng Liu, Jiawei Zhou, Jianqiang Guo, Deyong Ge, Jing Wu, Dong Hu
BACKGROUND: Cancer-associated fibroblasts (CAFs) play a crucial role in the tumor microenvironment of lung adenocarcinoma (LUAD) and are often associated with poorer clinical outcomes. This study aimed to screen for CAF-specific genes that could serve as promising therapeutic targets for LUAD. METHODS: We established a single-cell transcriptional profile of LUAD, focusing on genetic changes in fibroblasts. Next, we identified key genes associated with fibroblasts through weighted gene co-expression network analysis (WGCNA) and univariate Cox analysis...
March 21, 2024: BMC Medical Genomics
https://read.qxmd.com/read/38514660/tertiary-lymphoid-structures-and-b-cells-determine-clinically-relevant-t-cell-phenotypes-in-ovarian-cancer
#39
JOURNAL ARTICLE
Lenka Kasikova, Jana Rakova, Michal Hensler, Tereza Lanickova, Jana Tomankova, Josef Pasulka, Jana Drozenova, Katerina Mojzisova, Anna Fialova, Sarka Vosahlikova, Jan Laco, Ales Ryska, Pavel Dundr, Roman Kocian, Tomas Brtnicky, Petr Skapa, Linda Capkova, Marek Kovar, Jan Prochazka, Ivan Praznovec, Vladimir Koblizek, Alice Taskova, Hisashi Tanaka, Robert Lischke, Fernando Casas Mendez, Jiri Vachtenheim, Viola Heinzelmann-Schwarz, Francis Jacob, Iain A McNeish, Michal J Halaska, Lukas Rob, David Cibula, Sandra Orsulic, Lorenzo Galluzzi, Radek Spisek, Jitka Fucikova
Intratumoral tertiary lymphoid structures (TLSs) have been associated with improved outcome in various cohorts of patients with cancer, reflecting their contribution to the development of tumor-targeting immunity. Here, we demonstrate that high-grade serous ovarian carcinoma (HGSOC) contains distinct immune aggregates with varying degrees of organization and maturation. Specifically, mature TLSs (mTLS) as forming only in 16% of HGSOCs with relatively elevated tumor mutational burden (TMB) are associated with an increased intratumoral density of CD8+ effector T (TEFF ) cells and TIM3+ PD1+ , hence poorly immune checkpoint inhibitor (ICI)-sensitive, CD8+ T cells...
March 21, 2024: Nature Communications
https://read.qxmd.com/read/38513890/high-throughput-antigen-microarray-identifies-longitudinal-prognostic-autoantibody-for-chemoimmunotherapy-in-advanced-non-small-cell-lung-cancer
#40
JOURNAL ARTICLE
Liyuan Dai, Qiaoyun Tan, Lin Li, Ning Lou, Cuiling Zheng, Jianliang Yang, Liling Huang, Shasha Wang, Rongrong Luo, Guangyu Fan, Tongji Xie, Jiarui Yao, Zhishang Zhang, Le Tang, Yuankai Shi, Xiaohong Han
Chemoimmunotherapy has evolved as a standard treatment for advanced non-small cell lung cancer (aNSCLC). However, inevitable drug resistance has limited its efficacy, highlighting the urgent need for biomarkers of chemoimmunotherapy. A three-phase strategy to discover, verify, and validate longitudinal predictive autoantibodies (AAbs) for aNSCLC before and after chemoimmunotherapy was employed. A total of 528 plasma samples from 267 aNSCLC patients before and after anti-PD1 immunotherapy were collected, plus 30 independent formalin-fixed paraffin-embedded samples...
March 19, 2024: Molecular & Cellular Proteomics: MCP
keyword
keyword
168877
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.